Establishment Labs Holdings INC

Establishment Labs Holdings Inc. announced the appointment of Taylor Harris to its Board of Directors, effective immediately, bringing extensive experience in healthcare finance and leadership.

Establishment Labs Holdings Inc. shareholders re-elected all director nominees and ratified the appointment of its independent auditor at the 2026 Annual Meeting.

Establishment Labs Holdings Inc. announced first quarter 2026 financial results, showcasing significant revenue growth, improved gross margins, and a narrowed operating loss, leading to raised annual guidance.

Establishment Labs Holdings Inc. has entered into a new $300 million credit agreement to refinance existing debt and support general corporate operations.

Establishment Labs Holdings Inc. announced robust fourth-quarter and full-year 2025 financial results, alongside optimistic revenue guidance for 2026 and 2027.

Establishment Labs Holdings Inc. filed an 8-K to furnish presentation materials from its J.P. Morgan Healthcare Conference appearance.

Establishment Labs reported a 44.7% revenue increase to $59.9 million for Q1 2026, driven by strong U.S. market adoption of Motiva Implants.

Establishment Labs Holdings Inc. reported a 33.8% increase in Q3 revenue, driven by strong U.S. market penetration and improved gross margins, despite an increase in nine-month operating losses.

Establishment Labs Holdings Inc. reported increased revenue driven by U.S. market entry but saw wider net losses and significant cash burn in the second quarter of 2025.

Establishment Labs saw an 11.3% increase in revenue for the first quarter of 2025, fueled by strong U.S. sales following FDA approval of Motiva Implants.

Establishment Labs reported a decrease in revenue for the nine months ended September 30, 2024, alongside a net loss, while highlighting FDA approval for Motiva Implants and a new manufacturing facility.

Establishment Labs' Q2 2024 results show a revenue decrease of 9.3% compared to Q2 2023, alongside a net loss, while the company completed an FDA inspection of its Costa Rica facility.

Establishment Labs Holdings Inc. reported a 27.2% revenue increase to $211.1 million in 2025, driven by strong U.S. market entry and improved EMEA/Latin America demand, despite continued net losses.

Establishment Labs' 2024 results show a slight revenue increase, a larger net loss, and strategic developments including FDA approval in the U.S. and a CEO transition.

Establishment Labs' 2023 annual report highlights a modest revenue increase, ongoing losses, and strategic expansions in manufacturing and product availability.

Juan Jose Chacon Quiros, a Director at ESTA, acquired 11,315 common shares through an equity incentive plan award.

Nicholas Sheridan Lewin, a Director at Establishment Labs Holdings Inc. (ESTA), reported the acquisition of stock options on April 24, 2026.

Taylor C. Harris, a Director at ESTABLISHMENT LABS HOLDINGS INC., reported the acquisition of stock units under the company's 2018 Equity Incentive Plan.

Director Leslie Gillin acquired 196 shares of Establishment Labs Holdings Inc. common stock on June 30, 2026, as part of the Outside Director Compensation Policy.

Ann Custin, a Director at Establishment Labs Holdings Inc., received 239 common shares as a quarterly retainer payment, valued at $85.81 per share.

Director Nicholas Sheridan Lewin acquired 291 common shares of Establishment Labs Holdings Inc. (ESTA) valued at $85.81 each, electing to receive shares instead of a cash retainer.

Establishment Labs Holdings Inc. announces its 2026 Annual Meeting of Shareholders, scheduled for May 22, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Establishment Labs Holdings Inc. supplements its proxy statement to reflect the engagement of CBIZ CPAs P.C. as the new independent registered public accounting firm following Marcum LLP's resignation.

Establishment Labs Holdings Inc. has appointed Fillipo Peter Caldini, the interim CEO, as the permanent Chief Executive Officer and a Class II director, effective May 7, 2025, and May 24, 2025, respectively.

Establishment Labs Holdings Inc. has filed a definitive proxy statement with the SEC.

Establishment Labs Holdings Inc. will hold its 2025 Annual Meeting of Shareholders virtually on May 23, 2025, to vote on director elections, executive compensation, and the ratification of the company's accounting firm.

Establishment Labs Holdings Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting matters.

JW Asset Management, along with affiliated entities, has reported beneficial ownership of 9.15% of Establishment Labs Holdings, Inc. common stock as of June 30, 2026.

Brown Advisory Inc. and its subsidiaries have filed a Schedule 13G reporting a 5.38% beneficial ownership stake in Establishment Labs Holdings Inc.

Nantahala Capital Management and its principals have reduced their beneficial ownership in Establishment Labs Holdings Inc. to below 5%.

Brown Advisory Inc. and its affiliates reported a combined beneficial ownership of 7.02% in Establishment Labs Holdings Inc. as of December 31, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a beneficial ownership of up to 6.91% in Establishment Labs Holdings Inc. as of September 30, 2025.

Capital Research Global Investors has disclosed a 3.5% beneficial ownership stake in Establishment Labs Holdings Inc., holding 1,024,417 common shares.